Long-term and late effects of germ cell testicular cancer treatment and implications for follow-up Journal Article


Authors: Haugnes, H. S.; Bosl, G. J.; Boer, H.; Gietema, J. A.; Brydyø, M.; Oldenburg, J.; Dahl, A. A.; Bremnes, R. M.; Fossa, S. D.
Article Title: Long-term and late effects of germ cell testicular cancer treatment and implications for follow-up
Abstract: Germ cell testicular cancer (TC) represents a malignancy with high cure rates. Since the introduction of cisplatin-based chemotherapy in the late 1970s, the 5-year survival rate has increased considerably, and it is currently above 95%. Because TC is usually diagnosed before the age of 40 years, these men can expect to live for another 40 to 50 years after being successfully treated. This success, however, is hampered by an increased risk of long-term and late effects of treatment. Secondary malignant neoplasms and cardiovascular disease represent the most common potentially life-threatening late effects, typically occurring more than 10 years after treatment. Other long-term effects include pulmonary toxicity, nephrotoxicity, neurotoxicity, decreased fertility, hypogonadism, and psychosocial problems. The incidence and time to onset of these various adverse effects vary according to treatment type and intensity. There is still little knowledge about underlying mechanisms and genetic susceptibility of the various adverse effects. Apart from treatment burden, it is not yet possible to identify patients who are at high risk for certain late effects after TC treatment. In this clinical review, we present the current status regarding different somatic and psychosocial long-term late effects after treatment for TC, based on Medline searches and our own research. Moreover, we postulate recommendations for general medical evaluations that should begin after treatment is completed and continue during follow-up. © 2012 by American Society of Clinical Oncology.
Keywords: cancer survival; treatment outcome; fatigue; review; cisplatin; nonhuman; antineoplastic agents; neurotoxicity; follow up; metastasis; quality of life; nephrotoxicity; peripheral neuropathy; radiotherapy; medical assessment; survivors; sexuality; cardiovascular disease; cardiovascular diseases; genetic susceptibility; testicular neoplasms; cognition; neoplasms, germ cell and embryonal; neoplasms, second primary; hypogonadism; testis cancer; fertility; germ cell tumor; mental health; lifestyle; life style; raynaud phenomenon; ototoxicity; employment; avascular necrosis
Journal Title: Journal of Clinical Oncology
Volume: 30
Issue: 30
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2012-10-20
Start Page: 3752
End Page: 3763
Language: English
DOI: 10.1200/jco.2012.43.4431
PROVIDER: scopus
PUBMED: 23008318
DOI/URL:
Notes: --- - "Cited By (since 1996): 1" - "Export Date: 3 December 2012" - "CODEN: JCOND" - "Source: Scopus"
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. George Bosl
    430 Bosl